Information Provided By: 
Fly News Breaks for February 14, 2020
AGN, ABBV, BHVN
Feb 14, 2020 | 09:38 EDT
Piper Sandler analyst Tyler Van Buren said he has been tracking the early launch experience with AbbVie (ABBV) and Allergan's (AGN) Ubrelvy ahead of approval for Biohaven Pharmaceutical's (BHVN) rimegepant, which is "expected any day now." The initial Ubrelvy prescription trajectory indicates a strong demand for oral CGRPs to treat acute migraine, said Van Buren, who said Ubrelvy's trajectory bodes well for Biohaven's rimegepant, which he views as a superior product. The analyst has an Overweight rating and $100 price target on Biohaven shares.
News For BHVN;ABBV;AGN From the Last 2 Days
BHVN
Apr 23, 2024 | 09:00 EDT
UBS raised the firm's price target on Biohaven to $60 from $59 and keeps a Buy rating on the shares after hosting meetings with management. The stock's 28% selloff since April 15 represents an "attractive opportunity," the analyst tells investors in a research note. The firm sees an attractive risk/reward into the Phase 1 degrader data on May 29. A key opinion leader viewed Biohaven's degrader platform as an elegant approach to various disease modalities, says UBS. The firm says the stock's bear case is overdone.
